{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:26:17Z","timestamp":1792193177579,"version":"4.4.0"},"reference-count":38,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) can be transmitted by cellular blood products, leading to severe disease in immunosuppressed patients such as neonates and transplant recipients. To mitigate transfusion-transmitted CMV (TT-CMV), \u201cCMV-safe\u201d blood products (leukoreduced and\/or CMV-seronegative) are transfused. Attempts to develop practice guidelines for TT-CMV mitigation have been limited by paucity of high-quality clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To assess current TT-CMV mitigation strategies across medical institutions for specific at-risk populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Supplemental questions regarding TT-CMV and CMV disease mitigation were added to a College of American Pathologists Transfusion Medicine (Comprehensive) Participant Survey in 2015, addressing whether a given institution provided CMV-safe products for 6 at-risk patient populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Ninety percent (2712 of 3032) of institutions reported providing universally leukoreduced blood products. Among institutions without universal leukoreduction, 92% (295 of 320) provided leukoreduced products on the basis of clinical criteria. Eighty-three percent (2481 of 3004) of respondents reported having availability of CMV-seronegative products; however, wide variation in policies was reported governing CMV-seronegative product use. Among all respondents, less than 5% reported using CMV prophylaxis and monitoring in high-risk patient groups. Transplant centers reported higher rates of CMV prophylaxis (25% [97 of 394] solid organ) and monitoring (15% [59 of 394] solid organ) for CMV-negative transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Universal leukoreduction is the primary strategy for mitigating TT-CMV. While most institutions have both CMV-seronegative and leukoreduced blood products available, consensus is lacking on which patients should receive these products. High-quality studies are needed to determine if CMV-seronegative and leukoreduced blood products are needed in high-risk patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2016-0461-oa","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T09:39:46Z","timestamp":1503999586000},"page":"1705-1711","source":"Crossref","is-referenced-by-count":20,"title":["Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation"],"prefix":"10.5858","volume":"141","author":[{"given":"Stuart P.","family":"Weisberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Staley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Lance A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy P.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lohith S.","family":"Bachegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Ho","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth H.","family":"Shaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"issue":"1","key":"2020081217512799100_i1543-2165-141-12-1705-b01","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/tmrv.2001.19946","article-title":"Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction","volume":"15","author":"Blajchman","year":"2001","journal-title":"Transfus Med Rev"},{"issue":"4","key":"2020081217512799100_i1543-2165-141-12-1705-b02","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1046\/j.1537-2995.2001.41040560.x","article-title":"Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement","volume":"41","author":"Laupacis","year":"2001","journal-title":"Transfusion"},{"issue":"4","key":"2020081217512799100_i1543-2165-141-12-1705-b03","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"issue":"1","key":"2020081217512799100_i1543-2165-141-12-1705-b04","first-page":"103","article-title":"Complement-fixing antibodies against cytomegalovirus in different parts of the world","volume":"49","author":"Krech","year":"1973","journal-title":"Bull World Health Organ"},{"issue":"1","key":"2020081217512799100_i1543-2165-141-12-1705-b05","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0092-8674(01)80014-3","article-title":"Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors","volume":"91","author":"Soderberg-Naucler","year":"1997","journal-title":"Cell"},{"issue":"3","key":"2020081217512799100_i1543-2165-141-12-1705-b06","first-page":"236","article-title":"Posttransfusion cytomegalovirus infections","volume":"113","author":"Tegtmeier","year":"1989","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"2020081217512799100_i1543-2165-141-12-1705-b07","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/blood-2002-10-3143","article-title":"Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products","volume":"101","author":"Nichols","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2020081217512799100_i1543-2165-141-12-1705-b08","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1423-0410.2009.01228.x","article-title":"Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative","volume":"98","author":"Smith","year":"2010","journal-title":"Vox Sang"},{"issue":"6 suppl","key":"2020081217512799100_i1543-2165-141-12-1705-b09","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/01.ta.0000199537.09201.7b","article-title":"The clinical benefits of the leukoreduction of blood products","volume":"60","author":"Blajchman","year":"2006","journal-title":"J Trauma"},{"issue":"1","key":"2020081217512799100_i1543-2165-141-12-1705-b10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.0041-1132.2003.00518.x","article-title":"The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC","volume":"44","author":"Yazer","year":"2004","journal-title":"Transfusion"},{"issue":"4","key":"2020081217512799100_i1543-2165-141-12-1705-b11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0887-7963(98)80002-3","article-title":"Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions","volume":"12","author":"Vamvakas","year":"1998","journal-title":"Transfus Med Rev"},{"issue":"1","key":"2020081217512799100_i1543-2165-141-12-1705-b12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.0041-1132.2004.00608.x","article-title":"Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction","volume":"44","author":"Paglino","year":"2004","journal-title":"Transfusion"},{"issue":"5","key":"2020081217512799100_i1543-2165-141-12-1705-b13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/trf.12074","article-title":"Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections","volume":"53","author":"Ziemann","year":"2013","journal-title":"Transfusion"},{"issue":"10","key":"2020081217512799100_i1543-2165-141-12-1705-b14","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/trf.12199","article-title":"The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients","volume":"53","author":"Ziemann","year":"2013","journal-title":"Transfusion"},{"issue":"6","key":"2020081217512799100_i1543-2165-141-12-1705-b15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/cit945","article-title":"A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant","volume":"58","author":"Florescu","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2020081217512799100_i1543-2165-141-12-1705-b16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/infdis\/153.3.478","article-title":"Risk factors for cytomegalovirus infection after human marrow transplantation","volume":"153","author":"Meyers","year":"1986","journal-title":"J Infect Dis"},{"issue":"8649","key":"2020081217512799100_i1543-2165-141-12-1705-b17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(89)92330-1","article-title":"Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes: Neonatal Cytomegalovirus Infection Study Group","volume":"1","author":"Gilbert","year":"1989","journal-title":"Lancet"},{"issue":"16","key":"2020081217512799100_i1543-2165-141-12-1705-b18","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJM198604173141602","article-title":"Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation","volume":"314","author":"Bowden","year":"1986","journal-title":"N Engl J Med"},{"issue":"2","key":"2020081217512799100_i1543-2165-141-12-1705-b19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3476(81)80662-2","article-title":"Prevention of transfusion-acquired cytomegalovirus infections in newborn infants","volume":"98","author":"Yeager","year":"1981","journal-title":"J Pediatr"},{"issue":"1","key":"2020081217512799100_i1543-2165-141-12-1705-b20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood.V78.1.246.246","article-title":"Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant","volume":"78","author":"Bowden","year":"1991","journal-title":"Blood"},{"issue":"9","key":"2020081217512799100_i1543-2165-141-12-1705-b21","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598","article-title":"A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant","volume":"86","author":"Bowden","year":"1995","journal-title":"Blood"},{"issue":"12","key":"2020081217512799100_i1543-2165-141-12-1705-b22","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1537-2995.2011.03203.x","article-title":"Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME)","volume":"51","author":"Thiele","year":"2011","journal-title":"Transfusion"},{"issue":"12","key":"2020081217512799100_i1543-2165-141-12-1705-b23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.bbmt.2013.09.013","article-title":"Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?","volume":"19","author":"Kekre","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020081217512799100_i1543-2165-141-12-1705-b24","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1111\/j.1537-2995.2012.03739.x","article-title":"Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients","volume":"52","author":"Nash","year":"2012","journal-title":"Transfusion"},{"issue":"6, pt 2","key":"2020081217512799100_i1543-2165-141-12-1705-b25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/trf.13478","article-title":"Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis","volume":"56","author":"Mainou","year":"2016","journal-title":"Transfusion"},{"issue":"4","key":"2020081217512799100_i1543-2165-141-12-1705-b26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1537-2995.2009.02486.x","article-title":"Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction","volume":"50","author":"Wu","year":"2010","journal-title":"Transfusion"},{"key":"2020081217512799100_i1543-2165-141-12-1705-b27","unstructured":"National Center for Health Statistics. Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities. Hyattsville, MD; 2016."},{"issue":"5","key":"2020081217512799100_i1543-2165-141-12-1705-b28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.annemergmed.2012.02.020","article-title":"Distribution of specialized care centers in the United States","volume":"60","author":"Wang","year":"2012","journal-title":"Ann Emerg Med"},{"issue":"11","key":"2020081217512799100_i1543-2165-141-12-1705-b29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jamapediatrics.2014.1360","article-title":"Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study","volume":"168","author":"Josephson","year":"2014","journal-title":"JAMA Pediatr"},{"issue":"5","key":"2020081217512799100_i1543-2165-141-12-1705-b30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ajcp\/aqw181","article-title":"Survey of institutional policies for provision of \u201cCMV-safe\u201d blood in Ontario","volume":"146","author":"Finlay","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2020081217512799100_i1543-2165-141-12-1705-b31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.pcl.2012.12.008","article-title":"Congenital cytomegalovirus infection: new prospects for prevention and therapy","volume":"60","author":"Swanson","year":"2013","journal-title":"Pediatr Clin North Am"},{"issue":"5","key":"2020081217512799100_i1543-2165-141-12-1705-b32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rmv.1790","article-title":"Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?","volume":"24","author":"Cannon","year":"2014","journal-title":"Rev Med Virol"},{"issue":"9","key":"2020081217512799100_i1543-2165-141-12-1705-b33","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1055\/s-0036-1581080","article-title":"Symptomatic postnatal cytomegalovirus testing among very low-birth-weight infants: indications and outcomes","volume":"33","author":"Mukhopadhyay","year":"2016","journal-title":"Am J Perinatol"},{"issue":"4","key":"2020081217512799100_i1543-2165-141-12-1705-b34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"issue":"1","key":"2020081217512799100_i1543-2165-141-12-1705-b35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2020081217512799100_i1543-2165-141-12-1705-b36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"2020081217512799100_i1543-2165-141-12-1705-b37","article-title":"URGENT recall extension for Leukotrap RC System with RC2D Filter"},{"key":"2020081217512799100_i1543-2165-141-12-1705-b38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2393-13-96","article-title":"Cytomegalovirus in pregnancy: to screen or not to screen","volume":"13","author":"Walker","year":"2013","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/141\/12\/1705\/1445846\/arpa_2016-0461-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/141\/12\/1705\/1445846\/arpa_2016-0461-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:38:32Z","timestamp":1764790712000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/141\/12\/article-p1705.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2016-0461-oa","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}